Study to assess safety, tolerability and pharmacokinetics after single and multiple doses of AZD1446 to Japanese subject
Study identifier:D1950C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Young and Elderly Japanese Volunteers after Oral Single and Multiple Ascending Doses
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1446, Placebo
Sex
All
Actual Enrollment
97
Study type
Interventional
Age
20 Years - 80 Years
Date
Study Start Date: 01 Dec 2009
Primary Completion Date: 01 Jun 2010
Study Completion Date: 01 Jun 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD1446 | Drug: AZD1446 Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel. |
| Placebo Comparator: 2 Placebo | Drug: Placebo Oral solution Dose single and followed by 7-day multiple dosing. |
Contacts
Investigators
Principal Investigator
Björn Paulsson
AstraZeneca R&D Södertälje
